S-8 1 rcus_fy_2022_s-8.htm S-8 S-8

 

As filed with the Securities and Exchange Commission on February 28, 2023

Registration No. 333-

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM S-8

REGISTRATION STATEMENT

Under

The Securities Act of 1933

 

Arcus Biosciences, Inc.

(Exact name of Registrant as specified in its charter)

 

 

 

 

 

Delaware

 

47-3898435

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

3928 Point Eden Way

Hayward, CA 94545

(Address of Principal Executive Offices, Zip Code)

 

ARCUS BIOSCIENCES, INC. 2018 EQUITY INCENTIVE PLAN

ARCUS BIOSCIENCES, INC. 2018 EMPLOYEE STOCK PURCHASE PLAN

(Full title of plan)

 

Terry Rosen, Ph.D.

Chief Executive Officer

Arcus Biosciences, Inc.

3928 Point Eden Way

Hayward, CA 94545

(Name and address of agent for service)

(510) 694-6200

(Telephone number, including area code, of agent for service)

Please send copies of all communications to:

Kenneth L. Guernsey

Cooley LLP

101 California Street, 5th Floor

San Francisco, CA 94111

(415) 693-2000

 

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

 

Accelerated filer

Non-accelerated filer

 

 

Smaller reporting company

 

 

 

 

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act .

 

 


 

 

EXPLANATORY NOTE

Pursuant to General Instruction E to Form S-8, this Registration Statement is being filed with the U.S. Securities and Exchange Commission (the “Commission”) for the purpose of registering an additional number of securities of the same class as other securities for which a Registration Statement on Form S-8 relating to the same employee benefit plans is effective. Specifically, this Registration Statement is being filed to register (i) 2,916,602 additional shares of common stock of Arcus Biosciences, Inc. (the “Registrant”) for issuance under the Arcus Biosciences, Inc. 2018 Equity Incentive Plan and (ii) 729,150 additional shares of common stock of the Registrant for issuance under the Arcus Biosciences, Inc. 2018 Employee Stock Purchase Plan, in each case, pursuant to the provisions of such plans that provide for automatic annual increases in the number of shares reserved for issuance thereunder. This Registration Statement hereby incorporates by reference the contents of the Registrant’s Registration Statements on Form S-8 filed with the Commission on March 16, 2018 (File No. 333-223746), March 5, 2019 (File No. 333-230074), March 5, 2020 (File No. 333-236915), February 25, 2021 (File No. 333-253474) and February 23, 2022 (File No. 333-262929) (the "Prior Forms S-8") pursuant to General Instruction E to Form S-8.

 

PART II

Information Required in the Registration Statement

Item 3. Incorporation of Documents by Reference

The Registrant hereby incorporates by reference into this Registration Statement the Prior Forms S-8 and the following documents previously filed with the SEC:

 

 

(a)

the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on February 28, 2023; and

 

(b)

the description of the Registrant’s common stock contained in the Registrant’s Registration Statement on Form 8-A (File No. 001-38419), filed with the SEC on March 9, 2018, including any amendments or reports filed for the purpose of updating such description, including Exhibit 4.2 to the Registrant’s Annual Report on Form 10-K filed with the SEC on February 21, 2021.

All other reports and documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which de-registers all securities then remaining unsold shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents. The Registrant is not, however, incorporating any documents or information that the Registrant is deemed to furnish and not file in accordance with SEC rules. Any statement contained in a document incorporated or deemed incorporated by reference in this Registration Statement will be deemed modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document that also is deemed incorporated by reference in this Registration Statement modifies or supersedes that statement.

 


 

 

Item 8. Exhibits

 

 

 

 

Incorporated by Reference

 

 

Exhibit

Number

 

Description

 

Form

 

File No.

 

Exhibit

 

Filing
Date

 

Filed
Herewith

 

 

 

 

 

 

 

  4.1

 

Amended and Restated Certificate of Incorporation of Registrant.

 

10-Q

 

001-38419

 

3.1

 

5/9/2018

 

 

  4.2

 

Amended and Restated Bylaws of Registrant.

 

8-K

 

001-38419

 

3.1

 

5/26/2020

 

 

  5.1

 

Opinion of Cooley LLP.

 

 

 

 

 

 

 

 

 

X

23.1

 

Consent of Independent Registered Public Accounting Firm.

 

 

 

 

 

 

 

 

 

X

23.2

 

Consent of Cooley LLP (contained in Exhibit 5.1).

 

 

 

 

 

 

 

 

 

X

24.1

 

Power of Attorney (contained in the signature page hereto).

 

 

 

 

 

 

 

 

 

X

99.1

 

Arcus Biosciences, Inc. 2018 Equity Incentive Plan.

 

S-1/A

 

333-223086

 

10.3

 

3/5/2018

 

 

99.2

 

Arcus Biosciences, Inc. 2018 Employee Stock Purchase Plan.

 

S-1/A

 

333-223086

 

10.4

 

3/5/2018

 

 

107

 

Filing Fee Table.

 

 

 

 

 

 

 

 

 

X

 

 


 

 

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Hayward, State of California on this 28th day of February, 2023.

 

 

 

 

ARCUS BIOSCIENCES, INC.

 

 

By:

 

/s/ Terry Rosen

 

 

Terry Rosen, Ph.D.

Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS that each person whose signature appears below constitutes and appoints Terry Rosen, Ph.D. and Juan Carlos Jaen, Ph.D. and each of them, his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this registration statement, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorney-in-fact and agents or their substitute or substitutes may lawfully do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, each of the undersigned has executed this Power of Attorney as of the date indicated.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

 


 

Name

 

Title

 

Date

 

 

 

 

 

/s/ Terry Rosen

 

Chief Executive Officer and Director

 

February 28, 2023

Terry Rosen, Ph.D.

 

 (Principal Executive Officer)

 

 

 

 

 

 

 

/s/ Juan Carlos Jaen

 

President and Director

 

February 28, 2023

Juan Carlos Jaen, Ph.D.

 

 

 

 

 

 

 

 

 

/s/ Jennifer Jarrett

 

Chief Operating Officer and Director

 

February 28, 2023

Jennifer Jarrett

 

 

 

 

 

 

 

 

 

/s/ Robert C. Goeltz II

 

Chief Financial Officer

 

February 28, 2023

Robert C. Goeltz II

 

 (Principal Financial and Accounting Officer)

 

 

 

 

 

 

 

/s/ Kathryn Falberg

 

 Director

 

February 28, 2023

Kathryn Falberg

 

 

 

 

 

 

 

 

 

/s/ Linda Higgins

 

 Director

 

February 28, 2023

Linda Higgins, Ph.D.

 

 

 

 

 

 

 

 

 

/s/ Yasunori Kaneko

 

 Director

 

February 28, 2023

Yasunori Kaneko, M.D.

 

 

 

 

 

 

 

 

 

/s/ David Lacey

 

 Director

 

February 28, 2023

David Lacey, M.D.

 

 

 

 

 

 

 

 

 

/s/ Nicole Lambert

 

 Director

 

February 28, 2023

Nicole Lambert

 

 

 

 

 

 

 

 

 

/s/ Patrick Machado

 

 Director

 

February 28, 2023

Patrick Machado, J.D.

 

 

 

 

 

 

 

 

 

/s/ Merdad Parsey

 

 Director

 

February 28, 2023

Merdad Parsey, M.D., Ph.D.

 

 

 

 

 

 

 

 

 

/s/ Andrew Perlman

 

 Director

 

February 28, 2023

Andrew Perlman, M.D., Ph.D.

 

 

 

 

 

 

 

 

 

/s/ Antoni Ribas

 

Director

 

February 28, 2023

Antoni Ribas, M.D., Ph.D.